Amneal Pharmaceuticals, Inc. Class A (AMRX)

Amneal Pharmaceuticals' stock has trended upwards by 25.78% in the past six months. In February 2026, Amneal reported its Fourth Quarter and Full Year 2025 financial results, with all three business segments achieving double-digit revenue growth. In January 2026, Amneal Pharmaceuticals was added to the S&P SmallCap 600® Index. In March 2026, a co-founder exercised options and sold approximately $4.8 million worth of stock. In April 2026, the company announced the launch of Bimatoprost Ophthalmic Solution, 0.01%, and analysts have increased price targets for AMRX.

Demand for Amneal's pharmaceutical products can exhibit seasonality, influenced by factors such as disease incidence and weather conditions. Demand for cold and flu medications typically rises in winter, while hay fever medication demand increases in spring. The company's diverse portfolio likely experiences some demand fluctuation based on general industry trends.

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, and distributes essential medicines, operating in the Healthcare sector within the Drug Manufacturers - Other and Pharmaceutical Products industries. The company is segmented into Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment includes generics, injectables, and biosimilars across various therapeutic areas. The Specialty segment focuses on branded products for central nervous system and endocrine disorders, and Amneal is developing GLP-1 therapies. The AvKARE segment distributes pharmaceuticals to U.S. federal government agencies.

Amneal Pharmaceuticals has a global presence with operations in the U.S., India, and Ireland, including manufacturing plants and R&D centers. It has manufacturing facilities in New Jersey, New York, and Kentucky in the U.S., and in Ahmedabad, Dahej, Vizag, and Hyderabad in India. The company also has a commercial office in Mumbai, India, and facilities in Ireland focused on complex delivery formats. Amneal has been expanding its reach with product approvals and collaborations in China and a presence in Europe and Canada.

Amneal Pharmaceuticals' reputation has faced challenges due to regulatory issues. In August 2025, the FDA issued a warning letter citing manufacturing standard violations at its Gujarat, India, facility due to contaminated IV bags. In April 2026, the FDA's OPDP accused Amneal of producing "false and misleading" drug promotions for its biosimilar Alymsys.

As of December 2025, institutional investors held 47.9% of outstanding shares, with major holders including Vanguard Group Inc and BlackRock, Inc. Tushar Bhikhubhai Patel is the largest individual shareholder, owning 49.50% of the company. Other notable individual/insider owners include Gautam Patel, Dipan Patel, Chintu Patel, and Chirag K. Patel.